S
Synlogic D
D
SYBX
1.47000
USD
-0.03
(-2.00%)
مغلق
حجم التداول
0
الربح لكل سهم
-7
العائد الربحي
-
P/E
-16
حجم السوق
17,193,280
الأخبار المقالات
العنوان: Synlogic
القطاع: Healthcare
الصناعة: Biotechnology
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformativetreatments for serious diseases.